Technical Analysis for TYME - Tyme Technologies, Inc.

Grade Last Price % Change Price Change
grade F 1.38 0.00% 0.00
TYME closed unchanged on Friday, May 24, 2019, on 78 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 29

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical TYME trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%

Older signals for TYME ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company's another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company's therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
Biopharmaceutical Cancer Life Sciences Drug Development Cancer Therapeutics Millennium Pharmaceuticals Takeda Pharmaceutical Company
Is TYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.64
52 Week Low 1.3
Average Volume 347,984
200-Day Moving Average 2.4329
50-Day Moving Average 1.7114
20-Day Moving Average 1.512
10-Day Moving Average 1.462
Average True Range 0.1117
ADX 18.29
+DI 14.3752
-DI 24.3765
Chandelier Exit (Long, 3 ATRs ) 1.4049
Chandelier Exit (Short, 3 ATRs ) 1.6351
Upper Bollinger Band 1.6566
Lower Bollinger Band 1.3674
Percent B (%b) 0.04
BandWidth 19.126984
MACD Line -0.084
MACD Signal Line -0.085
MACD Histogram 0.001
Fundamentals Value
Market Cap 123.26 Million
Num Shares 89.3 Million
EPS -0.14
Price-to-Earnings (P/E) Ratio -9.86
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.55
Resistance 3 (R3) 1.54 1.47 1.52
Resistance 2 (R2) 1.47 1.43 1.48 1.51
Resistance 1 (R1) 1.43 1.41 1.40 1.44 1.50
Pivot Point 1.36 1.36 1.35 1.37 1.36
Support 1 (S1) 1.32 1.32 1.29 1.33 1.26
Support 2 (S2) 1.25 1.30 1.26 1.25
Support 3 (S3) 1.21 1.25 1.24
Support 4 (S4) 1.22